Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Echinacea purpurea

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    Query did not match any clinical trials.
    These are paediatric studies completed by 26 January 2007, in respect of products authorised in the Community (Article 45 of the Paediatric Regulation (EC) No 1901/2006).
    Note: Advanced search filters for country, trial phase, gender, rare disease, IMP with orphan designation in the indication and age ranges of in-utero, adult or elderly do not apply to these records.
    Study title: A double-blind, multicenter, multi-dose, parallel group, placebo-controlled study on the efficacy and safety of a homeopathic combination remedy vs.placebo over 14 days of treatment in children with acute otitis media.
    Active substance: Aconitum napellus Dil. D6 0,075 ml; Capsicum annuum Dil. D4 0,075 ml; Chamomilla recutita Ø 0,225 ml; Echinacea purpurea Ø 0,75 ml; Hydrargyrum bicyanatum Dil. D6 0,075 ml; Hydrastis canadensis Dil. D4 0,075 ml; Iodum Dil. D4 0,075 ml; Natrium tetraboracicum Dil. D4 0,075 ml; Sambucus nigra Ø 0,225 ml; Sanguinaria canadensis Ø 0,075 ml.
    Study summary document link (including results):
    View full study record
    Document reference: 39772
    Study title: E. Purpurea for prevention of upper respiratory tract infections in children; J of alternative & complementaryy medicine. Vol. 11(6) 2005, 1021-1026E. Purpurea for prevention of upper respiratory tract infections in children; J of alternative & complementaryy medicine. Vol. 11(6) 2005, 1021-1026
    Active substance: Echinacea purpurea extract (HERB)
    Study summary document link (including results):
    View full study record
    Document reference: 39867
    Study title: Efficacy and safety of Echinacea in treating upper respiratory tract infections; JAMA, 290 (21) 2003, 2824-2830Efficacy and safety of Echinacea in treating upper respiratory tract infections; JAMA, 290 (21) 2003, 2824-2830
    Active substance: Echinacea purpurea extract (HERB)
    Study summary document link (including results):
    View full study record
    Document reference: 39868
    Study title: Einfluss der immunstimulierenden Wirkung von Pressaft aus Herba ·Echinaceae purpureae auf Verlauf und Schweregrad von Erkältunngskrankheiten (EC31J0.05); Z. Für Immunbiologie in der Praxis, 2 (8), 1992, 18-22
    Active substance: Echinacea purpurea extract (HERB)
    Study summary document link (including results):
    View full study record
    Document reference: 39866
    Study title: Verification of the tolerability and efficacy for Echinacea STADA Junior used in supporting treatment of recurrent respiratory infections
    Active substance: Echinacea purpurea extract (HERB)
    Study summary document link (including results):
    View full study record
    Document reference: 39865
    Study title: Saunders P.R, Smith F, Schusky R.W.: Echinacea purpurea in children: safety, tolerability, compliance, and clinical effectiveness in upper respiratory tract infections. Can J Physiol Pharmacol. 2007 Nov; 85(11): 1195-1199
    Active substance: Dried, pressed plant sap of Echinacea purpurea 176 mg/tablet, corresponding to 4 g herbal drug/tablet
    Study summary document link (including results):
    View full study record
    Document reference: 39850
    Study title: Taylor J.A. et al: Efficacy and Safety of Echinacea in Treating Upper Respitatory Tract Infections in Children. A Randomised Controllled Trial; JAMA, Dec 3, 2003; vol 290, No 21, 2824-2830
    Active substance: Dried, pressed plant sap of Echinacea purpurea 176 mg/tablet, corresponding to 4 g herbal drug/tablet
    Study summary document link (including results):
    View full study record
    Document reference: 39848
    Study title: Weber, W. et al: Echinacea purpurea for prevention of upper respiratory tract infections in children. J Altern Complement Med. 2005 Dec; 11(6):1021-6
    Active substance: Dried, pressed plant sap of Echinacea purpurea 176 mg/tablet, corresponding to 4 g herbal drug/tablet
    Study summary document link (including results):
    View full study record
    Document reference: 39849
    Study title: study KLC 0016
    Active substance: Extrakt aus Rotem Sonnenhut (Echinacea purpurea) (HERB)
    Study summary document link (including results):
    View full study record
    Document reference: 39997
    Study title: study KLC 0018
    Active substance: Extrakt aus Rotem Sonnenhut (Echinacea purpurea) (HERB)
    Study summary document link (including results):
    View full study record
    Document reference: 39998
    Study title: study KLC 0019
    Active substance: Extrakt aus Rotem Sonnenhut (Echinacea purpurea) (HERB)
    Study summary document link (including results):
    View full study record
    Document reference: 39999
    Study title: Weber et al. THE JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE Volume 11, Number 6, 2005, pp. 1021–1026 Echinacea purpurea for Prevention of Upper Respiratory Tract Infections in Children
    Active substance: (HERB) Purple cone flower, pressed juice, 1.7 - 2.5 : 1
    Study summary document link (including results):
    View full study record
    Document reference: 39729
    Study title: Efficacy and safety of echinacea in treating upper respoiratory tract infections in children. A randomized controlled trial.Taylor JA, Weber W, Standish L et al. JAMA 2003;290: 2824-2830Efficacy and safety of echinacea in treating upper respoiratory tract infections in children. A randomized controlled trial.Taylor JA, Weber W, Standish L et al. JAMA 2003;290: 2824-2830
    Active substance: (HERB) Echinacea purpurea L extract
    Study summary document link (including results):
    View full study record
    Document reference: 39702
    Study title: Wber et al. Echinacea purpurea for Prevention of Upper Respiratory Tract Infections in Children; THE JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE Volume 11, Number 6, 2005, pp. 1021–1026
    Active substance: (HERB) Purple cone flower, dried pressed juice, 31.5 - 53.6 : 1
    Study summary document link (including results):
    View full study record
    Document reference: 39718
    Study title: Weber et al. Echinacea purpurea for Prevention of Upper Respiratory Tract Infections in Children; THE JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE Volume 11, Number 6, 2005, pp. 1021–1026
    Active substance: (HERB) Purple cone flower, dried pressed juice, 31.5 - 53.6 : 1, 85 %
    Study summary document link (including results):
    View full study record
    Document reference: 39720
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 18 13:05:49 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA